From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

EXPOSE: Celadon Pharmaceuticals – yarns of sales contracts ahead of placing that just don’t look quite right

By Tom Winnifrith | Wednesday 15 May 2024


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I really do not wish to get on the wrong side of FemiNazi PR bird Ms. Sarah MacLeod but, with a hat tip to Evil Banksta, I must warn her that her client Celadon Pharmaceuticals (CEL) seems to have rather over-egged news of new contract wins ahead of bailout placings last year. So here is the timeline that Ms. MacLeod, and the Oxymorons at AIM Regulation should be looking at:
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Ariana – Surprise!

Time left: 04:07:11